Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.

ME1100 (arbekacin inhalation solution) is an inhaled aminoglycoside that is being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken to evaluate ME1100 regimens for the treatment of patients with HABP/VABP. Data used included a population pharmacokinetic (PPK) model 4-compartment model with 1st-order elimination, non-clinical PK-PD targets from one-compartment in vitro and/or in vivo infection models, and in vitro surveillance data. Using the PPK model, total-drug epithelial lining fluid (ELF) concentration-time profiles were generated for simulated patients with varying creatinine clearance (CLcr; mL/min/1.73 m2). Percent probabilities of PK-PD target attainment by MIC were determined based on the ratio of total-drug ELF area under the concentration-time curve (AUC) to MIC (AUC:MIC ratio) targets associated with 1- and 2-log10 CFU reductions from baseline for Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus Percent probabilities of PK-PD target attainment based on PK-PD targets for a 1-log10 CFU reduction from baseline at MIC values above the MIC90 value for K. pneumoniae (8 μg/mL), P. aeruginosa (4 μg/mL), and S. aureus (0.5 μg/mL) were ≥99.8% for ME1100 600 mg twice daily (BID) in simulated patients with CLcr >80 to ≤120 mL/min/1.73 m2 ME1100 600 mg BID, 450 mg BID, 600 mg once daily in simulated patients with CLcr of >50 to ≤80, >30 to ≤50 and 0 to ≤30 mL/min/1.73 m2, respectively, provided arbekacin exposures that best matched those for 600 mg BID in simulated patients with normal renal function. These data provide support for ME1100 as a treatment for patients with HABP/VABP.